Skip to Main Content

Paper Details

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
Lancet
179
2017
5' UTR, HCV, HCV RNA, HIV infection, N-acetylgalactosamine, Patients, RG, RG-, RG-101, chronic HCV genotype 1 (, chronic HCV genotype 1, 3, or 4 infection, chronic HCV infection, chronic hepatitis C, decompensated liver disease, genome, hepatitis B virus, hepatitis C, hepatitis C virus, hepatocellular carcinoma, hepatocyte, interferon, men, miR, miR-122, miR-122 binding regions, patients, women

Datasets

Release 1.2